<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01770743</url>
  </required_header>
  <id_info>
    <org_study_id>EBS.AVA.208 / DMID 11-0055</org_study_id>
    <secondary_id>HHSN272201000035C</secondary_id>
    <nct_id>NCT01770743</nct_id>
  </id_info>
  <brief_title>A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels</brief_title>
  <official_title>A Phase 2, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study to Evaluate the Safety and Immunogenicity of AV7909 for Post-Exposure Prophylaxis of Anthrax Using Three Immunization Schedules and Two Dose Levels in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and immunogenicity of an anthrax vaccine.
      The vaccine schedule and dose will also be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The safety and immunogenicity of AV7909 for post-exposure prophylaxis of anthrax will be
      evaluated using a randomized, parallel-group, active-controlled, double-blind design with
      three immunization schedules and two dose levels in healthy adult volunteers. Safety will be
      assessed by clinical laboratory tests (hematology, serum chemistry, and urinalysis),
      monitoring of adverse events, vital signs, and physical examinations. Reactogenicity
      (systemic and injection site reactions) will be assessed by the subjects using subject
      e-diaries for 7 days after each immunization and by the investigator at in-clinic visits 7
      and 14 days after each immunization, and at other visits, if applicable. Immunogenicity will
      be measured as toxin neutralizing antibody (TNA) response and seroconversion rates.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxin Neutralizing Antibody (TNA) Level at Day 63</measure>
    <time_frame>Day 63</time_frame>
    <description>Immunogenicity measured by the lower bound (LB) of the 95% confidence intervals (CIs) for the proportion of subjects in each study arm with Day 63 TNA 50% neutralization factor (NF50) values greater than or equal to threshold</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>From the time of the first immunization on Day 0 through Day 84</time_frame>
    <description>Incidence of adverse events (including assessment of symptoms, physical exam findings, clinical laboratory tests, and vital signs) from the time of the first immunization on Day 0 through Day 84</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>From the time of the first immunization on Day 0 through the 12-month safety follow-up telephone call following the last scheduled vaccination</time_frame>
    <description>Incidence of serious adverse events, from the time of the first immunization on Day 0 through the 12-month safety follow-up telephone call following the last scheduled vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Reactogenicity By Severity</measure>
    <time_frame>For 7 days following each vaccination on Days 0, 14, 28</time_frame>
    <description>Incidence of solicited systemic reactions and solicited injection site reactions each day for 7 days following each vaccination using subject e-diaries by severity.
Reactions were graded using the following scale (note, for redness and swelling, the diameter [greater of two perpendicular measurements] was assessed by the subject using an injection site measurement tool):
Grade 0 (Absent): Symptom not present; Grade 1 (Mild): Symptom present but does not interfere with activities of daily living, or affected area (redness, swelling) measures &lt;3 cm; Grade 2 (Moderate): Symptom causes some interference with activities of daily living, or affected area (redness, swelling) measures 3 - 10 cm; Grade 3 (Severe): Symptom prevents activities of daily living or requires treatment, or affected area (redness, swelling) measures &gt; 10 cm.
For each reaction, subjects are counted once across all vaccinations at the highest reported level of severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Clinical Laborabory Abnormalities</measure>
    <time_frame>From the time of first immunization on Day 0 to Day 84</time_frame>
    <description>Incidence of clinical laboratory abnormalities throughout the study (up to Day 84).
Clinical laboratory abnormalities are presented as the total of Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), and Grade 4 (potentially life-threatening) abnormalities according to criteria adapted from the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research: Guidance for Industry. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (September 2007). Within each laboratory parameter, subjects are counted once for their most severe occurrence of clinical laboratory abnormality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Immunologically Significant Adverse Events of Special Interest</measure>
    <time_frame>From the time of the first immunization on Day 0 through the 12-month safety follow-up telephone call following the last scheduled vaccination</time_frame>
    <description>Incidence of immunologically significant adverse events of special interest as defined by the Center for Biologics Evaluation and Research from the time of the first immunization on Day 0 through the 12-month safety follow-up telephone call following the last scheduled vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TNA Level at Day 42</measure>
    <time_frame>Day 42</time_frame>
    <description>Immunogenicity measured by the percentage of subjects in each study arm with Day 42 TNA NF50 values greater than or equal to threshold</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNA Level at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Immunogenicity measured by the percentage of subjects with Day 28 TNA NF50 values greater than or equal to threshold</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNA Seroconversion Rate</measure>
    <time_frame>Up to Day 84</time_frame>
    <description>Immunogenicity measured by the percentage of subjects who have seroconverted (defined as a 4-fold increase over Day 0 in TNA NF50 value) at Days 21, 28, 35, 42, 49, 63, and 84</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Anthrax</condition>
  <arm_group>
    <arm_group_label>AV7909 (Day 0 and 14)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV7909 (Day 0 and 28)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV7909 (Day 0, 14, and 28)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV7909 Reduced Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BioThrax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AV7909</intervention_name>
    <description>Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
    <arm_group_label>AV7909 (Day 0 and 14)</arm_group_label>
    <arm_group_label>AV7909 (Day 0 and 28)</arm_group_label>
    <arm_group_label>AV7909 (Day 0, 14, and 28)</arm_group_label>
    <arm_group_label>AV7909 Reduced Dose</arm_group_label>
    <other_name>AV7909 Anthrax Vaccine</other_name>
    <other_name>NuThrax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BioThrax</intervention_name>
    <arm_group_label>BioThrax</arm_group_label>
    <other_name>Anthrax Vaccine Adsorbed (AVA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be 18-50 years old

          -  Be in good health

          -  Have access to a computer and the internet so you can complete a diary

          -  Agree to abstain from sex the first 84 days of the study or practice birth control if
             you are a woman who is able to get pregnant

          -  Have not donated blood for the previous 8 weeks

        Exclusion Criteria:

          -  A known anaphylactic response, severe systemic response, or serious hypersensitivity
             reaction to a prior immunization.

          -  A history of latex allergy.

          -  Have received a shot (vaccine), including flu shots, in the past 6 weeks or plan to
             get a shot for 4 weeks after the last study shot is given.

          -  Have previously served in the military any time after 1990 or plan to enlist in the
             military from Screening through Day 84.

          -  Prior immunization with anthrax vaccine, recombinant protective antigen (rPA) vaccine,
             or known exposure to anthrax organisms.

          -  Have participated in anthrax therapeutic or vaccine studies (monoclonal anti-PA or
             anthrax immune globulins or anthrax vaccines).

          -  Participation in any investigational study involving use of a pharmacological
             intervention within 30 days before the Screening visit or planning to participate in a
             study requiring dosing through the 12-month safety follow-up telephone call.

          -  Have a known diagnosis of any immunodeficiency disease including but not limited to:
             acquired immune deficiency syndrome (AIDS), common variable immunodeficiency disease,
             immunoglobulin A (IgA) deficiency, or hypogammaglobulinemia.

          -  Past history of significant autoimmune disease such as rheumatoid arthritis, lupus
             erythematous, psoriasis in the area of vaccinations, or requires immunotherapy,
             glomerulonephritis, or autoimmune thyroiditis.

          -  Have received immunosuppressive therapy with cytotoxic drugs or Rituximab within the
             past 2 years.

          -  A history of cytotoxic chemotherapy or radiation therapy.

          -  Chronic (&gt;10 days) daily oral or parenteral corticosteroid therapy in the past 12
             months.

          -  Any lung disease, including reactive airway disease, which requires the daily use of
             medications.

          -  A female currently breastfeeding or with a positive pregnancy test.

          -  A history of drug or alcohol abuse within 12 months prior to Screening, or a positive
             result on a urine drug screen for cocaine, marijuana, opiates, methamphetamines,
             benzodiazepines, or oxycodone.

          -  Any tattoo or other skin condition in the deltoid region on either arm that may
             obscure the assessment of the injection sites.

          -  A medical condition that, in the opinion of the PI or designee, could adversely impact
             the subject's participation or safety or the conduct of the study.

          -  Any planned elective in-patient surgery during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gurdyal Kalsi, MD, MTOPRA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emergent BioSolutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Costal Carolina Research</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Allergy and Asthma</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2013</study_first_submitted>
  <study_first_submitted_qc>January 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2013</study_first_posted>
  <results_first_submitted>February 6, 2015</results_first_submitted>
  <results_first_submitted_qc>February 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 24, 2015</results_first_posted>
  <last_update_submitted>February 6, 2015</last_update_submitted>
  <last_update_submitted_qc>February 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post-exposure prophylaxis</keyword>
  <keyword>toxin neutralization assay</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anthrax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 16 January 2013 to 14 November 2013 at 4 medical centers in the United States.</recruitment_details>
      <pre_assignment_details>All 168 enrolled participants who met eligibility criteria were dosed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AV7909 (Day 0 and 14)</title>
          <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
        </group>
        <group group_id="P2">
          <title>AV7909 (Day 0 and 28)</title>
          <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
        </group>
        <group group_id="P3">
          <title>AV7909 (Day 0, 14, and 28)</title>
          <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
        </group>
        <group group_id="P4">
          <title>AV7909 Reduced Dose</title>
          <description>Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
        </group>
        <group group_id="P5">
          <title>BioThrax</title>
          <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
BioThrax</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="44"/>
                <participants group_id="P5" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="44"/>
                <participants group_id="P5" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="42"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Terminated Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moving Out of State</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat Population</population>
      <group_list>
        <group group_id="B1">
          <title>AV7909 (Day 0 and 14)</title>
          <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
        </group>
        <group group_id="B2">
          <title>AV7909 (Day 0 and 28)</title>
          <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
        </group>
        <group group_id="B3">
          <title>AV7909 (Day 0, 14, and 28)</title>
          <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
        </group>
        <group group_id="B4">
          <title>AV7909 Reduced Dose</title>
          <description>Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
        </group>
        <group group_id="B5">
          <title>BioThrax</title>
          <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
BioThrax</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="44"/>
            <count group_id="B5" value="23"/>
            <count group_id="B6" value="168"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.4" spread="9.0"/>
                    <measurement group_id="B2" value="32.7" spread="9.7"/>
                    <measurement group_id="B3" value="29.7" spread="10.2"/>
                    <measurement group_id="B4" value="32.8" spread="9.2"/>
                    <measurement group_id="B5" value="32.5" spread="10.4"/>
                    <measurement group_id="B6" value="32.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Toxin Neutralizing Antibody (TNA) Level at Day 63</title>
        <description>Immunogenicity measured by the lower bound (LB) of the 95% confidence intervals (CIs) for the proportion of subjects in each study arm with Day 63 TNA 50% neutralization factor (NF50) values greater than or equal to threshold</description>
        <time_frame>Day 63</time_frame>
        <population>Per-protocol Population at Day 63 (randomized subjects who did not have any deviation of 1) history of anthrax vaccination; 2) missing or out of window vaccination at Day 14 or 28; 3) incorrect IMP dose at one or more visits; 4) IMP dose associated with a temperature excursion; 5) prohibited medications; or 6) missing Day 63 immunogenicity data).</population>
        <group_list>
          <group group_id="O1">
            <title>AV7909 (Day 0 and 14)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O2">
            <title>AV7909 (Day 0 and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O3">
            <title>AV7909 (Day 0, 14, and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O4">
            <title>AV7909 Reduced Dose</title>
            <description>Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O5">
            <title>BioThrax</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
BioThrax</description>
          </group>
        </group_list>
        <measure>
          <title>Toxin Neutralizing Antibody (TNA) Level at Day 63</title>
          <description>Immunogenicity measured by the lower bound (LB) of the 95% confidence intervals (CIs) for the proportion of subjects in each study arm with Day 63 TNA 50% neutralization factor (NF50) values greater than or equal to threshold</description>
          <population>Per-protocol Population at Day 63 (randomized subjects who did not have any deviation of 1) history of anthrax vaccination; 2) missing or out of window vaccination at Day 14 or 28; 3) incorrect IMP dose at one or more visits; 4) IMP dose associated with a temperature excursion; 5) prohibited medications; or 6) missing Day 63 immunogenicity data).</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" lower_limit="39.5" upper_limit="72.9"/>
                    <measurement group_id="O2" value="100" lower_limit="87.2" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="81.5" upper_limit="100"/>
                    <measurement group_id="O4" value="90.2" lower_limit="76.9" upper_limit="97.3"/>
                    <measurement group_id="O5" value="52.4" lower_limit="29.8" upper_limit="74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events</title>
        <description>Incidence of adverse events (including assessment of symptoms, physical exam findings, clinical laboratory tests, and vital signs) from the time of the first immunization on Day 0 through Day 84</description>
        <time_frame>From the time of the first immunization on Day 0 through Day 84</time_frame>
        <population>Safety Population (subjects who received at least one dose of IMP)</population>
        <group_list>
          <group group_id="O1">
            <title>AV7909 (Day 0 and 14)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O2">
            <title>AV7909 (Day 0 and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O3">
            <title>AV7909 (Day 0, 14, and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O4">
            <title>AV7909 Reduced Dose</title>
            <description>Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O5">
            <title>BioThrax</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
BioThrax</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Incidence of adverse events (including assessment of symptoms, physical exam findings, clinical laboratory tests, and vital signs) from the time of the first immunization on Day 0 through Day 84</description>
          <population>Safety Population (subjects who received at least one dose of IMP)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TNA Level at Day 42</title>
        <description>Immunogenicity measured by the percentage of subjects in each study arm with Day 42 TNA NF50 values greater than or equal to threshold</description>
        <time_frame>Day 42</time_frame>
        <population>Per-protocol Population at Day 63 (randomized subjects who did not have any deviation of 1) history of anthrax vaccination; 2) missing or out of window vaccination at Day 14 or 28; 3) incorrect IMP dose at one or more visits; 4) IMP dose associated with a temperature excursion; 5) prohibited medications; or 6) missing Day 63 immunogenicity data).</population>
        <group_list>
          <group group_id="O1">
            <title>AV7909 (Day 0 and 14)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O2">
            <title>AV7909 (Day 0 and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O3">
            <title>AV7909 (Day 0, 14, and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O4">
            <title>AV7909 Reduced Dose</title>
            <description>Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O5">
            <title>BioThrax</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
BioThrax</description>
          </group>
        </group_list>
        <measure>
          <title>TNA Level at Day 42</title>
          <description>Immunogenicity measured by the percentage of subjects in each study arm with Day 42 TNA NF50 values greater than or equal to threshold</description>
          <population>Per-protocol Population at Day 63 (randomized subjects who did not have any deviation of 1) history of anthrax vaccination; 2) missing or out of window vaccination at Day 14 or 28; 3) incorrect IMP dose at one or more visits; 4) IMP dose associated with a temperature excursion; 5) prohibited medications; or 6) missing Day 63 immunogenicity data).</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5" lower_limit="71.2" upper_limit="95.5"/>
                    <measurement group_id="O2" value="100" lower_limit="86.8" upper_limit="100"/>
                    <measurement group_id="O3" value="94.4" lower_limit="72.7" upper_limit="99.9"/>
                    <measurement group_id="O4" value="97.6" lower_limit="87.1" upper_limit="99.9"/>
                    <measurement group_id="O5" value="70.0" lower_limit="45.7" upper_limit="88.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TNA Level at Day 28</title>
        <description>Immunogenicity measured by the percentage of subjects with Day 28 TNA NF50 values greater than or equal to threshold</description>
        <time_frame>Day 28</time_frame>
        <population>Per-protocol Population at Day 63 (randomized subjects who did not have any deviation of 1) history of anthrax vaccination; 2) missing or out of window vaccination at Day 14 or 28; 3) incorrect IMP dose at one or more visits; 4) IMP dose associated with a temperature excursion; 5) prohibited medications; or 6) missing Day 63 immunogenicity data).</population>
        <group_list>
          <group group_id="O1">
            <title>AV7909 (Day 0 and 14)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O2">
            <title>AV7909 (Day 0 and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O3">
            <title>AV7909 (Day 0, 14, and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O4">
            <title>AV7909 Reduced Dose</title>
            <description>Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O5">
            <title>BioThrax</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
BioThrax</description>
          </group>
        </group_list>
        <measure>
          <title>TNA Level at Day 28</title>
          <description>Immunogenicity measured by the percentage of subjects with Day 28 TNA NF50 values greater than or equal to threshold</description>
          <population>Per-protocol Population at Day 63 (randomized subjects who did not have any deviation of 1) history of anthrax vaccination; 2) missing or out of window vaccination at Day 14 or 28; 3) incorrect IMP dose at one or more visits; 4) IMP dose associated with a temperature excursion; 5) prohibited medications; or 6) missing Day 63 immunogenicity data).</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8" lower_limit="68.0" upper_limit="93.8"/>
                    <measurement group_id="O2" value="11.1" lower_limit="2.4" upper_limit="29.2"/>
                    <measurement group_id="O3" value="94.4" lower_limit="72.7" upper_limit="99.9"/>
                    <measurement group_id="O4" value="63.4" lower_limit="46.9" upper_limit="77.9"/>
                    <measurement group_id="O5" value="47.6" lower_limit="25.7" upper_limit="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TNA Seroconversion Rate</title>
        <description>Immunogenicity measured by the percentage of subjects who have seroconverted (defined as a 4-fold increase over Day 0 in TNA NF50 value) at Days 21, 28, 35, 42, 49, 63, and 84</description>
        <time_frame>Up to Day 84</time_frame>
        <population>Per-protocol Population at Day 63 (randomized subjects who did not have any deviation of 1) history of anthrax vaccination; 2) missing or out of window vaccination at Day 14 or 28; 3) incorrect IMP dose at one or more visits; 4) IMP dose associated with a temperature excursion; 5) prohibited medications; or 6) missing Day 63 immunogenicity data).</population>
        <group_list>
          <group group_id="O1">
            <title>AV7909 (Day 0 and 14)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O2">
            <title>AV7909 (Day 0 and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O3">
            <title>AV7909 (Day 0, 14, and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O4">
            <title>AV7909 Reduced Dose</title>
            <description>Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O5">
            <title>BioThrax</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
BioThrax</description>
          </group>
        </group_list>
        <measure>
          <title>TNA Seroconversion Rate</title>
          <description>Immunogenicity measured by the percentage of subjects who have seroconverted (defined as a 4-fold increase over Day 0 in TNA NF50 value) at Days 21, 28, 35, 42, 49, 63, and 84</description>
          <population>Per-protocol Population at Day 63 (randomized subjects who did not have any deviation of 1) history of anthrax vaccination; 2) missing or out of window vaccination at Day 14 or 28; 3) incorrect IMP dose at one or more visits; 4) IMP dose associated with a temperature excursion; 5) prohibited medications; or 6) missing Day 63 immunogenicity data).</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9" lower_limit="46.2" upper_limit="79.2"/>
                    <measurement group_id="O2" value="55.6" lower_limit="35.3" upper_limit="74.5"/>
                    <measurement group_id="O3" value="77.8" lower_limit="52.4" upper_limit="93.6"/>
                    <measurement group_id="O4" value="22.0" lower_limit="10.6" upper_limit="37.6"/>
                    <measurement group_id="O5" value="14.3" lower_limit="3.0" upper_limit="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" lower_limit="85.8" upper_limit="99.9"/>
                    <measurement group_id="O2" value="40.7" lower_limit="22.4" upper_limit="61.2"/>
                    <measurement group_id="O3" value="94.4" lower_limit="72.7" upper_limit="99.9"/>
                    <measurement group_id="O4" value="92.7" lower_limit="80.1" upper_limit="98.5"/>
                    <measurement group_id="O5" value="57.1" lower_limit="34.0" upper_limit="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="85.1" upper_limit="99.9"/>
                    <measurement group_id="O2" value="96.3" lower_limit="81.0" upper_limit="99.9"/>
                    <measurement group_id="O3" value="100" lower_limit="81.5" upper_limit="100"/>
                    <measurement group_id="O4" value="95.0" lower_limit="83.1" upper_limit="99.4"/>
                    <measurement group_id="O5" value="66.7" lower_limit="41.0" upper_limit="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" lower_limit="85.8" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100" lower_limit="86.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="81.5" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="91.4" upper_limit="100"/>
                    <measurement group_id="O5" value="95.0" lower_limit="75.1" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9" lower_limit="78.1" upper_limit="98.3"/>
                    <measurement group_id="O2" value="100" lower_limit="85.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="81.5" upper_limit="100"/>
                    <measurement group_id="O4" value="97.6" lower_limit="87.1" upper_limit="99.9"/>
                    <measurement group_id="O5" value="95.0" lower_limit="75.1" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5" lower_limit="71.2" upper_limit="95.5"/>
                    <measurement group_id="O2" value="100" lower_limit="87.2" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="81.5" upper_limit="100"/>
                    <measurement group_id="O4" value="97.6" lower_limit="87.1" upper_limit="99.9"/>
                    <measurement group_id="O5" value="85.7" lower_limit="63.7" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7" lower_limit="58.8" upper_limit="88.2"/>
                    <measurement group_id="O2" value="100" lower_limit="86.8" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="81.5" upper_limit="100"/>
                    <measurement group_id="O4" value="97.4" lower_limit="86.5" upper_limit="99.9"/>
                    <measurement group_id="O5" value="63.2" lower_limit="38.4" upper_limit="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Serious Adverse Events</title>
        <description>Incidence of serious adverse events, from the time of the first immunization on Day 0 through the 12-month safety follow-up telephone call following the last scheduled vaccination</description>
        <time_frame>From the time of the first immunization on Day 0 through the 12-month safety follow-up telephone call following the last scheduled vaccination</time_frame>
        <population>Safety Population (subjects who received at least one dose of IMP)</population>
        <group_list>
          <group group_id="O1">
            <title>AV7909 (Day 0 and 14)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O2">
            <title>AV7909 (Day 0 and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O3">
            <title>AV7909 (Day 0, 14, and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O4">
            <title>AV7909 Reduced Dose</title>
            <description>Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O5">
            <title>BioThrax</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
BioThrax</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events</title>
          <description>Incidence of serious adverse events, from the time of the first immunization on Day 0 through the 12-month safety follow-up telephone call following the last scheduled vaccination</description>
          <population>Safety Population (subjects who received at least one dose of IMP)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Reactogenicity By Severity</title>
        <description>Incidence of solicited systemic reactions and solicited injection site reactions each day for 7 days following each vaccination using subject e-diaries by severity.
Reactions were graded using the following scale (note, for redness and swelling, the diameter [greater of two perpendicular measurements] was assessed by the subject using an injection site measurement tool):
Grade 0 (Absent): Symptom not present; Grade 1 (Mild): Symptom present but does not interfere with activities of daily living, or affected area (redness, swelling) measures &lt;3 cm; Grade 2 (Moderate): Symptom causes some interference with activities of daily living, or affected area (redness, swelling) measures 3  10 cm; Grade 3 (Severe): Symptom prevents activities of daily living or requires treatment, or affected area (redness, swelling) measures &gt; 10 cm.
For each reaction, subjects are counted once across all vaccinations at the highest reported level of severity.</description>
        <time_frame>For 7 days following each vaccination on Days 0, 14, 28</time_frame>
        <population>Safety Population (subjects who received at least one dose of IMP)</population>
        <group_list>
          <group group_id="O1">
            <title>AV7909 (Day 0 and 14)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O2">
            <title>AV7909 (Day 0 and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O3">
            <title>AV7909 (Day 0, 14, and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O4">
            <title>AV7909 Reduced Dose</title>
            <description>Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O5">
            <title>BioThrax</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
BioThrax</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Reactogenicity By Severity</title>
          <description>Incidence of solicited systemic reactions and solicited injection site reactions each day for 7 days following each vaccination using subject e-diaries by severity.
Reactions were graded using the following scale (note, for redness and swelling, the diameter [greater of two perpendicular measurements] was assessed by the subject using an injection site measurement tool):
Grade 0 (Absent): Symptom not present; Grade 1 (Mild): Symptom present but does not interfere with activities of daily living, or affected area (redness, swelling) measures &lt;3 cm; Grade 2 (Moderate): Symptom causes some interference with activities of daily living, or affected area (redness, swelling) measures 3  10 cm; Grade 3 (Severe): Symptom prevents activities of daily living or requires treatment, or affected area (redness, swelling) measures &gt; 10 cm.
For each reaction, subjects are counted once across all vaccinations at the highest reported level of severity.</description>
          <population>Safety Population (subjects who received at least one dose of IMP)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue/Tiredness Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue/Tiredness Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue/Tiredness Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Ache Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Ache Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Ache Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warmth Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warmth Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Warmth Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Motion Limitation Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Motion Limitation Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Motion Limitation Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lump Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lump Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lump Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruise Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruise Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruise Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Clinical Laborabory Abnormalities</title>
        <description>Incidence of clinical laboratory abnormalities throughout the study (up to Day 84).
Clinical laboratory abnormalities are presented as the total of Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), and Grade 4 (potentially life-threatening) abnormalities according to criteria adapted from the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research: Guidance for Industry. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (September 2007). Within each laboratory parameter, subjects are counted once for their most severe occurrence of clinical laboratory abnormality.</description>
        <time_frame>From the time of first immunization on Day 0 to Day 84</time_frame>
        <population>Safety Population (subjects who received at least one dose of IMP)</population>
        <group_list>
          <group group_id="O1">
            <title>AV7909 (Day 0 and 14)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O2">
            <title>AV7909 (Day 0 and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O3">
            <title>AV7909 (Day 0, 14, and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O4">
            <title>AV7909 Reduced Dose</title>
            <description>Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O5">
            <title>BioThrax</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
BioThrax</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Clinical Laborabory Abnormalities</title>
          <description>Incidence of clinical laboratory abnormalities throughout the study (up to Day 84).
Clinical laboratory abnormalities are presented as the total of Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), and Grade 4 (potentially life-threatening) abnormalities according to criteria adapted from the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research: Guidance for Industry. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (September 2007). Within each laboratory parameter, subjects are counted once for their most severe occurrence of clinical laboratory abnormality.</description>
          <population>Safety Population (subjects who received at least one dose of IMP)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose Fasting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Urea Nitrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Erythrocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Immunologically Significant Adverse Events of Special Interest</title>
        <description>Incidence of immunologically significant adverse events of special interest as defined by the Center for Biologics Evaluation and Research from the time of the first immunization on Day 0 through the 12-month safety follow-up telephone call following the last scheduled vaccination</description>
        <time_frame>From the time of the first immunization on Day 0 through the 12-month safety follow-up telephone call following the last scheduled vaccination</time_frame>
        <population>Safety Population (subjects who received at least one dose of IMP)</population>
        <group_list>
          <group group_id="O1">
            <title>AV7909 (Day 0 and 14)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O2">
            <title>AV7909 (Day 0 and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O3">
            <title>AV7909 (Day 0, 14, and 28)</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O4">
            <title>AV7909 Reduced Dose</title>
            <description>Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
          </group>
          <group group_id="O5">
            <title>BioThrax</title>
            <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
BioThrax</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Immunologically Significant Adverse Events of Special Interest</title>
          <description>Incidence of immunologically significant adverse events of special interest as defined by the Center for Biologics Evaluation and Research from the time of the first immunization on Day 0 through the 12-month safety follow-up telephone call following the last scheduled vaccination</description>
          <population>Safety Population (subjects who received at least one dose of IMP)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing of the ICF to the first immunization on Day 0 (AEs recorded only if resulting from a study-related procedure) then through Day 84.</time_frame>
      <desc>AEs were collected at study visits on Days 0, 7, 14, 21, 28, 35, 42, 49, 63, and 84, and at the early withdrawal visit. The occurrence of SAEs and adverse events of special interest (autoimmune-related) were collected at safety follow-up phone contacts at 6 and 12 months following the last scheduled vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>AV7909 (Day 0 and 14)</title>
          <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
        </group>
        <group group_id="E2">
          <title>AV7909 (Day 0 and 28)</title>
          <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
        </group>
        <group group_id="E3">
          <title>AV7909 (Day 0, 14, and 28)</title>
          <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
        </group>
        <group group_id="E4">
          <title>AV7909 Reduced Dose</title>
          <description>Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
AV7909: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant</description>
        </group>
        <group group_id="E5">
          <title>BioThrax</title>
          <description>Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
BioThrax</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>cellulitis secondary to animal bite</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis neonatal</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>infant of subject experienced one lung underinflated following delivery by precautionary C-section at 36 weeks because of the subject's bicornuate uterus</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="44"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="10" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Respiratory rate increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="9" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="44"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor is responsible for public disclosure of study data. Any proposed publication is subject to review agreed between the Division of Microbiology and Infectious Diseases (DMID) and Emergent; between Emergent and the contract research organizations (CROs)/vendors; and between the CROs and the site Principal Investigator. Data are the property of the sponsor and cannot be published without prior authorization from the sponsor, but data and publication thereof will not be unduly withheld.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A few events collected in e-diary were downgraded (severe to moderate) on verification by the PI but were unable to be corrected in subjects' e-diary data: headache &amp; fatigue/tenderness in 2 subjects each; muscle ache &amp; pain &amp; AML in 1 subject each.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Gurdyal Kalsi</name_or_title>
      <organization>Emergent BioSolutions</organization>
      <phone>301-216-9927</phone>
      <email>kalsig@ebsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

